UFP Tech reported FY 2025 net sales of USD 602.8 million, up 19.5%, and net income of USD 68.3 million, up 15.8%. FY 2025 diluted EPS was USD 8.75 (+15.4%); adjusted net income was USD 76.1 million (+12.7%) and adjusted diluted EPS was USD 9.76. FY 2025 operating income rose 14.1% to USD 92.3 million, while adjusted EBITDA increased to USD 121.1 million from FY 2024. In Q4 2025, UFP Tech posted net sales of USD 148.9 million (+3.4%) and net income of USD 17.6 million; diluted EPS was USD 2.25 and adjusted EBITDA was USD 28.3 million. Q4 gross margin was 28.2% and FY gross margin was 28.3%; the company said it incurred USD 6.3 million of incremental labor cost at its AJR facility in Illinois during FY 2025 (USD 1.2 million in Q4) tied to previously disclosed workforce attrition related to associates’ eligibility to work in the U.S. By end market, FY 2025 medical sales increased 23.2% to USD 555.3 million, while non-medical sales decreased 11.5% to USD 47.5 million. The company also reported organic sales growth of approximately 1.5% in FY 2025. Operationally, UFP Tech said it extended its contract with its largest customer in La Romana through 2029, launched new programs in the Dominican Republic, took possession of a fifth building in 2025 and expects to add a sixth facility, and plans to add a new Santiago facility in Q2 2026 to support Safe Patient Handling program localization and ramp-up.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UFP Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241630PRIMZONEFULLFEED9660546) on February 24, 2026, and is solely responsible for the information contained therein.
Comments